Giuseppe Morgia1, Giorgio Ivan Russo2, Andrea Tubaro3, Roberto Bortolus4, Donato Randone5, Pietro Gabriele6, Fabio Trippa7, Filiberto Zattoni8, Massimo Porena9, Vincenzo Mirone10, Sergio Serni11, Alberto Del Nero12, Giancarlo Lay13, Umberto Ricardi14, Francesco Rocco15, Carlo Terrone16, Arcangelo Pagliarulo17, Giuseppe Ludovico18, Giuseppe Vespasiani19, Maurizio Brausi20, Claudio Simeone21, Giovanni Novella22, Giorgio Carmignani23, Rosario Leonardi24, Paola Pinnarò6, Ugo De Paula25, Renzo Corvò26, Raffaele Tenaglia27, Salvatore Siracusano28, Giovanna Mantini29, Paolo Gontero30, Gianfranco Savoca31, Vincenzo Ficarra32. 1. Department of Urology, University of Catania, Catania, Italy. 2. Department of Urology, University of Catania, Catania, Italy. Electronic address: giorgioivan@virgilio.it. 3. Sant' Andrea Hospital, Department of Urology, "La Sapienza" University of Roma, Roma, Italy. 4. S.O. Oncologia Radioterapica, Pordenone, Italy. 5. Urology, Presidio Ospedaliero Gradenigo, Torino, Italy. 6. Radiotherapy, IRCC Candiolo, Torino, Italy. 7. Radiotherapy, A.O. Santa Maria, Terni, Italy. 8. Department of Urology, University of Padova, Padova, Italy. 9. Department of Urology, University of Perugia, Perugia, Italy. 10. Department of Urology, Università Federico II of Napoli, Napoli, Italy. 11. Department of Urology, University of Firenze, Firenze, Italy. 12. Urologia I, Azienda Ospedaliera San Paolo, Milano, Italy. 13. Radiotherapy, ASL of Cagliari, Cagliari, Italy. 14. Radiotherapy, AOU University S. Giovanni Battista Molinette, Torino, Italy. 15. Department of Urology, University of Milano, Milano, Italy. 16. Urology, University Hospital "Maggiore della Carità", Novara, Italy. 17. Urology, University of Bari, Bari, Italy. 18. Urology, Ospedale Generale Regionale F. Miulli, Italy. 19. Department of Urology, University Tor Vergata, Roma, Italy. 20. Urology, Ospedale Civile Ramazzini, Carpi, Italy. 21. Department of Urology, University of Brescia, Brescia, Italy. 22. Department of Surgery, Urology Clinic, AOUI Verona, Verona, Italy. 23. Department of Urology, University of Genova, Genova, Italy. 24. Urology, Centro Uro-Andrologico La CURA, Acireale, Italy. 25. Radiotherapy, AO S. Giovanni Addolorata, Roma, Italy. 26. Radiotherapy, Istituto Nazionale per la Ricerca, Genova, Italy. 27. Department of Urology, University of Chieti, Chieti, Italy. 28. Department of Urology, University of Trieste, Trieste, Italy. 29. Radiotherapy, Policlinico Universitario Agostino Gemelli, Roma, Italy. 30. Department of Surgical Sciences, Città della Salute e della Scienza, University of Torino, Torino, Italy. 31. Urology, Fondazione Istituto San Raffaele-G. Giglio di Cefalù, Cefalù, Italy. 32. Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy.
Abstract
OBJECTIVE: To analyze the prevalence of cardiovascular disease (CVD) and osteoporosis in patients treated with androgen deprivation therapy (ADT) for prostate cancer (PCa) but not adherent to European Association of Urology (EAU) guidelines. MATERIALS AND METHODS: The CHOosIng Treatment for Prostate CanCEr (CHOICE) study was an Italian multicenter, cross-sectional study conducted from December 2010 to January 2012. A total of 1386 patients treated with ADT for PCa (first prescription or renewal of ADT) were selected. According to EAU guidelines, the cohort was categorized in discordant ADT (Group A) and concordant ADT (Group B). The prevalence of CVD and osteoporosis after ADT was recorded. RESULTS: The final cohort included 1075 patients. According to EAU guidelines adherence, 285 (26.51%) and 790 (73.49%) were considered discordant and concordant, respectively. The proportion of men with Charlson Comorbidity Index > 2 at baseline was statistically similar in Group A (81.8%) compared to Group B (80.8%) (P = .96). The number of complications reported at enrollment was as follows: cardiovascular in 351 (32.7%), endocrine in 166 (15.4%), sexual in 498 (46.3%), osteoporosis in 181 (16.8%), and gynecomastia in 274 (25.5%) subjects. At the multivariate logistic regression analysis adjusted for confounding factors, discordant ADT was associated with greater risk of cardiovascular complications (odds ratio: 2.07; P < .01) and osteoporosis (odds ratio: 1.75; P = .04). CONCLUSION: About one-third of patients with PCa received inappropriate ADT and showed a greater risk of CVD and osteoporosis. These results could be useful for setting better policy strategies to limit the inappropriateness of ADT prescription.
OBJECTIVE: To analyze the prevalence of cardiovascular disease (CVD) and osteoporosis in patients treated with androgen deprivation therapy (ADT) for prostate cancer (PCa) but not adherent to European Association of Urology (EAU) guidelines. MATERIALS AND METHODS: The CHOosIng Treatment for Prostate CanCEr (CHOICE) study was an Italian multicenter, cross-sectional study conducted from December 2010 to January 2012. A total of 1386 patients treated with ADT for PCa (first prescription or renewal of ADT) were selected. According to EAU guidelines, the cohort was categorized in discordant ADT (Group A) and concordant ADT (Group B). The prevalence of CVD and osteoporosis after ADT was recorded. RESULTS: The final cohort included 1075 patients. According to EAU guidelines adherence, 285 (26.51%) and 790 (73.49%) were considered discordant and concordant, respectively. The proportion of men with Charlson Comorbidity Index > 2 at baseline was statistically similar in Group A (81.8%) compared to Group B (80.8%) (P = .96). The number of complications reported at enrollment was as follows: cardiovascular in 351 (32.7%), endocrine in 166 (15.4%), sexual in 498 (46.3%), osteoporosis in 181 (16.8%), and gynecomastia in 274 (25.5%) subjects. At the multivariate logistic regression analysis adjusted for confounding factors, discordant ADT was associated with greater risk of cardiovascular complications (odds ratio: 2.07; P < .01) and osteoporosis (odds ratio: 1.75; P = .04). CONCLUSION: About one-third of patients with PCa received inappropriate ADT and showed a greater risk of CVD and osteoporosis. These results could be useful for setting better policy strategies to limit the inappropriateness of ADT prescription.
Authors: Sakthivel Muniyan; Lei Xi; Kaustubh Datta; Anindita Das; Benjamin A Teply; Surinder K Batra; Rakesh C Kukreja Journal: Biochim Biophys Acta Rev Cancer Date: 2020-06-11 Impact factor: 10.680
Authors: Markus Wallner; Mounir Khafaga; Ewald Kolesnik; Aris Vafiadis; Gerold Schwantzer; Deborah M Eaton; Pero Curcic; Martin Köstenberger; Igor Knez; Peter P Rainer; Martin Pichler; Burkert Pieske; Dirk Von Lewinski Journal: Oncotarget Date: 2017-07-25